Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 31, 2019, Benjamin Harshbarger resigned from his positions as the Interim Chief Executive Officer, principal executive officer and General Counsel of Novelion Therapeutics Inc. (the "Company"), effective immediately.




Item 8.01. Other Events.

As previously announced, on November 18, 2019, the Company filed application materials with the Supreme Court of British Columbia (the "Court") seeking various orders related to the voluntary liquidation and dissolution of the Company pursuant to the Business Corporations Act (British Columbia) (the "Liquidation"). The foregoing application is scheduled to be heard by the Court on January 9, 2020 (the "Hearing"). If the Court grants the requested orders at the Hearing, the Company intends to file with the British Columbia Registrar of Companies a Statement of Intent to Liquidate indicating that, among other things, the effective date and time for the commencement of implementation of the Liquidation (the "Effective Date") will be January 9, 2020 at 5:00 p.m. Pacific Time.

On January 3, 2020, the Company issued a press release providing an update on its liquidation process and related matters, including the Hearing and the Effective Date, which press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 8.01 by reference.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits.


Exhibit No.    Description
  99.1           Press Release, dated January 3, 2020.
104            Cover Page Interactive Data File (embedded within the Inline XBRL
               document).




                                       2

© Edgar Online, source Glimpses